survival was observed in p-ANCA/MPO patients than c-ANCA-PR3 and ANCA negative patients (Log rank test: p=0.04).

At univariate analysis of baseline data, deceased patients resulted older at disease onset (p=0.001) with more comorbidities (p<0.001) and presented at diagnosis a higher frequency of respiratory failure (p=0.002, OR 7.1; 95%CI: 2.2–22.2) and renal insufficiency (p=0.003, OR 4.7; 95%CI: 1.6 to 13.7). No significant differences were noted in term of infections/year, relapses/year and cancer development.

Conclusions: In this large cohort of Italian patients we confirm a higher short and long-term survival in AAV patient than reported in literature. Nevertheless, up to one third of deaths occurred within 6 months after diagnosis and infection diseases resulted the most frequent cause of death. Moreover, our data confirm the prognostic importance of ANCA pattern and the poor outcome of patient with severe lung and renal involvement.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018: Tapering and flaring in PsA and SpA

OP0334

EFFICACY AND SAFETY OF CONTINUING VERSUS WITHDRAWING ADALIMUMAB (ADA) IN MAINTAINING REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSAP)

1University of Amsterdam, Amsterdam, Netherlands; 2Charité Universitätsmedizin Berlin, Berlin, Germany; 3Swedish Medical Center and University of Washington, Seattle, USA; 4University of Toronto, Toronto, Canada; 5AbbVie Inc., North Chicago, USA

Background: It is not known whether TNF blockers can be stopped in nr-axSpA patients (pts) who are in remission.

Objectives: ABILITY-3, reported here, assessed if ADA can be discontinued or should be continued in nr-axSpA pts in sustained remission after a 28-wk open-label period.

Methods: ABILITY-3 enrolled adult pts diagnosed with nr-axSpA, fulfilling ASAS criteria but NOT modified New York criteria who had objective evidence of active MRI inflammation in the SI joints or spine or elevated high-sensitivity CRP at screening. active disease at baseline (ASDAS ≥2.1, BASDAI ≤4, total back pain >4), and inadequate response to ≥2 NSAIDs. Pts who achieved ASDAS inactive disease (ASDAS <1.3) with open-label ADA 40 mg every other wk at wk 16, 20, 24, and 28 were randomised to 40-wk, double-blind PBO (withdrawal) or ADA (continuation) in period 2. Primary efficacy endpoint was proportion of pts who did not experience a flare (ASDAS >2.1 at 2 consecutive study visits) during period 2. Secondary endpoints were also assessed up to wk 68 (nonresponder imputation).

Results: Of 673 enrolled pts, 305 (45%) were randomised to double-blind treatment. A significantly greater proportion of pts treated with ADA vs PBO had no flares (70% vs 47%; p<0.001) at wk 68; relative risk of flare with treatment withdrawal was 1.77. Time to flare analysis showed significantly lower risk of flare for ADA vs PBO (figure 1). At wk 68, significantly greater proportions of ADA vs PBO pts achieved secondary endpoints, except for HAQ-S (table 1). Among pts who received ADA at any time, 77% reported adverse events (AEs) and 4% reported a serious AE; nasopharyngitis (17%), upper respiratory tract infection (12%), worsening of axSpA (9%), headache (8%), and diarrhoea (6%) were the most common. During period 2, incidence of AEs was similar for ADA and PBO (65% vs 69%), incidence of serious AEs was higher for PBO vs ADA (7% vs 1%), and the most common AEs in both the ADA and PBO groups were nasopharyngitis (16% vs 13%), upper respiratory tract infection (13% vs 8%), and worsening of axSpA (6% vs 14%); none serious.

Abstract OP0334 – Table 1 Efficacy outcomes at week 68

<table>
<thead>
<tr>
<th>Week 68, n (%)</th>
<th>ADA (40 mg EOW) n=152</th>
<th>PBO n=153</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No flare</td>
<td>106 (70)</td>
<td>72 (47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ASDAS ID</td>
<td>87 (57)</td>
<td>51 (33)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ASDAS SI</td>
<td>89 (59)</td>
<td>49 (32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BASDAI 4</td>
<td>102 (67)</td>
<td>69 (45)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BASDAI 20</td>
<td>107 (70)</td>
<td>72 (47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BASDAI 40</td>
<td>100 (66)</td>
<td>70 (46)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ASDAS 5/6</td>
<td>87 (57)</td>
<td>49 (32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ASDAS 10/20</td>
<td>84 (54)</td>
<td>41 (27)</td>
<td>0.005</td>
</tr>
<tr>
<td>BASDAI 50</td>
<td>103 (68)</td>
<td>72 (47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Change from baseline in BASFI, LSmean(SE)</td>
<td>-3.97±0.11</td>
<td>-3.51±0.13</td>
<td>0.007</td>
</tr>
<tr>
<td>n=111</td>
<td>n=77</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline in HAQ-S, LSmean(SE)</td>
<td>-0.68±0.04</td>
<td>-0.50±0.04</td>
<td>0.088</td>
</tr>
<tr>
<td>n=112</td>
<td>n=79</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusions: In pts with nr-axSpA who achieved sustained remission with ADA, continued therapy was associated with significantly more pts maintaining remission and lower disease activity than treatment withdrawal. These results support the continuation of ADA therapy after achievement of sustained remission. Safety findings were consistent with established safety profile of ADA.

Acknowledgements: AbbVie funded, contributed to design, data collection, analysis and interpretation of the data of the study, and in writing, review, approval of the publication. Medical writing: Maria Hovenden, PhD; Janet E. Matsuura, PhD; of CPS; funded by AbbVie.


OP0335

HIGH NEED FOR ANTI-TNF THERAPY AFTER WITHDRAWAL STRATEGY IN EARLY PERIPHERAL SPONDYLOARTHRITIS

P. Carron1,2, G. Varks3,2, T. Penson3,2, A-S. De Craemer1,2, T. Renson1,2, A.-S. De Craemer1,2, D. Elewaut1,2, F. Van den Bosch1,2,1, Rheumatology; 2VIB Inflammation Research Center, University of Gent, Gent, Belgium

Background: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease. 1 When remission is reached, the recently updated T2T-recommendations suggest tapering of treatment. In the CRESPA-trial pSpA patients were treated with golimumab monotherapy; we demonstrated that – after reaching sustained remission – discontinuation of golimumab led to biological-free remission in 53% of patients; conversely 47% experienced a disease flare. It is currently unknown if concomitant administration of DMARDs could lead to higher rates of biological-free remission.

Objectives: To explore – in pSpA patients in clinical remission – the possibility that co-medication with methotrexate would allow discontinuation of the TNFi.

Methods: The CRESPA-trial included patients with active pSpA and symptom duration <12 weeks; the primary study results have been reported previously (reference). In the CRESPA-Extension protocol, patients were included that either did not reach remission (but had substantial improvement with golimumab treatment), or that experienced recurrence of arthritis, enthesis or dactylitis within 1 year after discontinuation of golimumab. These patients received additional open-label golimumab 50 mg SC every 4 weeks for 2 years. At week 104, patients were offered an additional 12 weeks of golimumab treatment, but now in combination with methotrexate 15 mg weekly. At week 116, patients in clinical remission continued methotrexate, but discontinued golimumab. Patients were prospectively followed to assess the rate of sustained biological-free clinical remission. In
The effect of timing and duration of statin-based clinical database, who had THA/TKA from 1988 revision (HR (95% CI) 0.74 (0.62, 0.88)).

Pants exposed for more than 5 years in total (vs <1 year) had a reduced risk of (0.65, 0.90), respectively, while first exposure >5 years following THA/TKA was imputed by chained equations with 10 iterations.

The study score for statin exposure in each period, which was calculated using a logistic regression was used for the analyses with adjustment for potential confounders.

Conclusions: Statin therapy initiated up to 5 years following THA/TKA may reduce the risk of revision arthroplasty. The mechanisms by which statin therapy is linked with a reduced risk of revision surgery are not completely understood, though does not appear to be related solely to an effect on osseointegration of the primary prosthesis, which occurs primarily in the early (<1 year) postoperative period.

Acknowledgements: The authors are grateful to the John Charnley Trust and the Three Wishes Foundation for supporting this research.

Disclosure of Interest: None declared


OP0336

THE EFFECT OF TIMING AND DURATION OF STATIN EXPOSURE ON THE RISK OF REVISION FOLLOWING TOTAL HIP OR KNEE ARTHROPLASTY: A POPULATION-BASED COHORT STUDY

M. Cook1, A.K. Sorial2, M. Lunt1, T. Board3, T. Jones3, M. Goodman2,3.

Objectives: To determine whether the timing of statin exposure relative to the primary arthroplasty influences the risk of revision arthroplasty. Also to determine whether the duration of exposure is associated with the risk of revision arthroplasty.

Methods: Subjects from the Clinical Practice Research Datalink, a population-based clinical database, who had THA/TKA from 1988–2016 were included. Cox regression models were used to determine the association between statin exposure and the risk of revision THA/TKA, i) at any time and ii) if first exposed 0–1, 1–5, or >5 years following THA/TKA. Cox regression was also used to determine the association between total duration of statin exposure (<1, 1–2, 2–4, 4–5, 5–8 years) and revision risk. The Cox regression models were adjusted for the propensity score for statin exposure in each period, which was calculated using a logistic regression model including demographic factors, selected comorbidities and selected medication. Missing data for covariates were imputed using multiple imputation by chained equations with 10 iterations.

Results: Of the original 60 pSpA patients included in the CRESPA-trial, completed the 2 year CRESPA-Extension protocol; of these, 21 (91%) were in clinical remission at week 104 when methotrexate was added. The mean follow-up period after completion of the extension part, was 80±28 w. 5 patients (24%) are still in sustained remission (n=5) under methotrexate mono-therapy whereas in 16 patients (76%), golimumab needed to be re-installed because of relapse of disease activity (n=14) or development of adverse events related to methotrexate (n=2). Recurrence of disease was characterised by development of arthritis in all patients with a median of 4 tender and 3 swollen joints. In 50% (n=7) of the cases, concomitant dactylitis was present. 64% (9/14) were having concomitant psoriasis which was mild since all had a BSA <5%. The mean time for recurrence was 28.6 weeks. Restarting golimumab treatment promptly restored clinical remission of all patients within 12 weeks.

Conclusions: In patients with pSpA in clinical remission after 2 years of golimu- mab monotherapy, concomitant administration of methotrexate before discontinuation of the TNFi, did not significantly raise the percentage of patients in biological-free remission. In 76% of patients, golimumab had to be restarted, underscoring the overall weak efficacy of methotrexate in pSpA.

Reference:

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4287

FRIDAY, 15 JUNE 2018: Prevention of OA: Yes we can!

OP0338

ASSOCIATION BETWEEN METABOLIC SYNDROME AND TRAJECTORIES OF KNEE PAIN: A 10.7-YEAR FOLLOW-UP STUDY

F. Pan1, J. Tian1, F. Cicuttin2, C. Ding1, G. Jones1, M. Menzies Institute for Medical Research, University of Tasmania, Hobart; 2Department of Epidemiology and Preventive Medicine, Monash University Medical School, Melbourne, Australia

Background: Metabolic syndrome (MetS) has been suggested as having a role in the pathogenesis of osteoarthritis (OA). However, no study has assessed whether MetS and its components are associated with knee pain and its change over time.

Objectives: To identify distinct trajectories of MSP over 10.7 years in an older population, and to examine risk factors for identified trajectories.

Methods: 1099 participants (mean age 63 years) from the population-based Tasmanian Older Adult Cohort study were recruited at baseline. 875, 768 and 563 participants attended years 2, 5.1 and 10.7 follow-up, respectively. Demographic, psychological, lifestyle and comorbidities data were obtained at baseline. Knee radiographic OA was assessed by X-ray at baseline. Group-based trajec- tory modelling was applied to identify distinct trajectories of MSP. Multivariable logistic regression was used for the analyses with adjustment for potential confounders.

Results: 985 participants were included for the analyses, three pain trajectories were identified: ‘Mild pain’ (52%), ‘Moderate pain’ (33%) and ‘Severe pain’ (15%) with 32% of participants having MetS. MetS was significantly associated with increased risk of both ‘Moderate pain’ (relative risk [RR]: 1.47, 95% confidence interval [CI]: 1.10 to 1.96) and ‘Severe pain’ (2.22, 1.54 to 3.20) relative to ‘Mild pain’ in univariate analysis. After adjustment for age, sex, smoking, physical activity, emotional problems, comorbidities and radiographic OA, central obesity was associated with increased risk of both ‘Moderate pain’ (1.70, 1.17 to 2.49) and ‘Severe pain’ (3.28, 2.16 to 4.98), and MetS and its components (hypertiglyceri- demia and low HDL) were only associated with increased risk of ‘Severe pain’ (p<0.05).

However, these associations became weak and non-significant after fur- ther adjustment for body mass index (BMI), but hypertension became significantly protective with ‘Moderate pain’ (0.70, 0.50 to 0.99). Similar associations were found in those with knee OA (RR: 1.70 to 2.75, all p<0.05).

Conclusions: The MetS is predominantly associated with knee pain trajectories through central obesity, and hypertiglyceridemia and low HDL can predict ‘Severe pain’ trajectory in those with MetS. An unexpected inverse association between hypertension and moderate pain trajectory needs a further investigation, which may reflect an interaction between blood pressure and pain sensitivity in ‘Moderate pain’ trajectory.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018

Big data for musculoskeletal research

OP0339

RELATIONSHIP OF PROVIDER DENSITY ON TOTAL JOINT REPLACEMENT OUTCOMES

B. Mehta1,2,7, J. Szymonikia, S. Dey3, I.Y. Navarro-Millan1,2, L. Mandl1,2, A. R. Bass1,2, L. Russeau1,2, M.L. Parks2, M.P. Figge2,4, J.T. Nguyen5, S. M. Goodman1,2,7, Columbia Mailman School of Public Health; 2Rheumatology, Weill Cornell Medicine; 3Biostatistics, Hospital for Special Surgery; 4Orthopaedics, Weill Cornell Medicine; 5Orthopaedics, Hospital for Special Surgery, New York, USA

Background: The proportion of providers in a geographical location (provider density) has been associated with improved surgical outcomes in hand and wrist surgery, appendicitis and other high-volume procedures, demonstrating the importance of access to care.

Objectives: The purpose of this study is to assess the association of provider density with Total Knee Replacement (TKR) and Total Hip Replacement (THR) outcomes.

Conclusions: Statin therapy initiated up to 5 years following THA/TKA may reduce the risk of revision arthroplasty. The mechanisms by which statin therapy is linked with a reduced risk of revision surgery are not completely understood, though does not appear to be related solely to an effect on osseointegration of the primary prosthesis, which occurs primarily in the early (<1 year) postoperative period.

Acknowledgements: The authors are grateful to the John Charnley Trust and the Three Wishes Foundation for supporting this research.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4287

FRIDAY, 15 JUNE 2018